Li Y, Yu Y, Wang Y, Lu J, et al. Ixekizumab four-week dosing is comparable to two-week dosing in psoriasis patients and reduces treatment costs: experience in a real-world setting over a 12-week period. Eur J Dermatol 2022;32:618-622.
PMID: 36468729